Brian O'Sullivan – författare

Prognostic Factors in Cancer, Third Edition examines the prognostic factors associated with each cancer site and provides insight into potential treatments and therapies. The text is an extension of the International Union Against Cancer's (UICC) seminal work, the TNM Classification of Malignant Tumours, and integrates the current focus on prognostics in cancer. This Third Edition reflects the advances in cancer diagnosis and treatment planning made in recent years. The first part of the book offers a complete update on the science of cancer prognosis while the second part contains site-specific chapters that provide evidence-based guidelines for treatment. Each clinical chapter summarizes the significance of the great variety of tumour-related, patient-related, and environment-related factors that play a role in the prognosis of cancer, all backed with a grid for quick reference.Visit TNM Online at: www.mrw.interscience.wiley.com/tnm to find the complete text of the previous edition of Prognostic Factors in Cancer, as well as other supplemental material related to cancer staging and predictive indicators.Prognostic Factors in Cancer, Third Edition is an invaluable resource for all oncologists and cancer researchers. The title is also of interest for other professionals such as pathologists and epidemiologists.

The essential reference on cancer stage returns as a fully revised edition Describing cancer stage is one of the most important elements of oncological practice. Clinical research and clinical care depend on an accurate assessment of cancer stage and prognostic factors. The TNM Classification of Malignant Tumours serves as the globally recognised standard reference for describing cancer stage and assessing treatment results. Now fully updated to reflect the results of the latest clinical research, it is indispensable for all clinicians, cancer registrars and researchers who work with malignant tumours. Readers of the ninth edition of TNM Classification of Malignant Tumours will find: Updates in many tumour sites including, nasopharynx, HPV associated oropharynx, lung, thymus, mesothelioma, appendix, anal canal, cervix, vulva and prostate carcinoma;Revised and updated sections on Essential TNM and paediatric cancer staging;New classifications for medulloblastoma, cutaneous lymphoma, parathyroid carcinoma, adrenal medulla and extra-adrenal paraganglia tumours;Revised classification of prognostic factors for many malignancies.TNM Classification of Malignant Tumours is an essential resource for anyone involved in cancer care, research or cancer control.

From Crisis to Crisis examines the impact of the harsh conditions of the interwar economy on the British merchant banks.  The financial crises of 1914 and 1931 are assessed using primary sources. The competitive threats, including the rise of New York as a rival financial centre, are considered. It challenges alleged special treatment and provides fresh perspectives on the interwar rationalisation of industry. During the late nineteenth century, Britain’s merchant banks had become pre-eminent in a world of fixed exchange rates, free trade and the unfettered mobility of international capital. This world was increasingly challenged in the interwar period, being replaced by floating exchange rates, trade protectionism and restrictions on capital movements.This book fills a gap in the historiography of British banking by recovering the histories of long-forgotten merchant banks rather than focusing on the better-known firms. Using a wide range of archival resources, it traces the strategic transformation by some merchant banks from higher-risk, capital intensive activities to lower-risk, advisory services. Brian O’Sullivan has been jointly awarded the 2019 BAC Wadsworth Prize for From Crisis to Crisis: The Transformation of Merchant Banking 1914-1939. It was judged by the Business Archives Council (BAC) to have made an outstanding contribution to the study of British business history. Brian shared the prize with Professor Priya Satia of Stanford University in California.

This open access book discusses the most current issues in head and neck cancer with a focus on current trends such as biomarkers, precision medicine and immunotherapy. New approaches in the diagnosis such as liquid biopsies and imaging biomarkers to predict radiotherapy toxicity as well as approaches in the surgical management of head and neck cancers are discussed. The book discusses medical and surgical approaches in both primary, recurrent and metastatic disease and also covers approaches for rare head neck cancers.  Readers will learn about the latest drug developments and epidemiological aspects in cancers ranging from Head and Neck Squamous Cell Cancer to Nasopharynx cancer.Edited by a team of world leaders in Head and Neck Cancer, this volume serves as an easy reference to the head and neck oncology practitioner and provides a contemporary overview for specialists the field. The chapters are based on the latest data presented at the 7th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.

This is an open access book.With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up.All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.

This is an open access book.With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up.All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.

This book is the first comprehensive history of the British Trade Corporation, which was constituted under a Royal Charter on 21st April 1917. Its charter was meant to last for sixty years, but in 1926, after a turbulent existence of only nine years, it was amalgamated with the Anglo-Austrian Bank, and absorbed into the Anglo-International Bank. The corporation together with its two main subsidiaries, the Levant Company and the National Bank of Turkey, conducted business not only in Britain but in Russia, Turkey, the Middle East and in Continental Europe. Although the corporation was not an agent of empire, it reflected Britain’s imperialistic ambitions after the First World War. As a result, it invested in some of the most unstable regions of the world. It was also severely affected by British foreign policy, which was often misjudged and, at times, duplicitous, resulting in serious damage to British trade. Within five years of its launch, the British Trade Corporation needed to be refinanced. The economic downturn in the early 1920s and ongoing hostilities in Eastern Europe and the Near East meant that it struggled to survive. Its difficulties reflected many of those faced by Britain in general after the war and the need to come to terms with the new realities of the post-war world.Despite its innovative attempt to address the perceived deficiencies in Britain’s financial system, especially in respect of industrial finance, the British Trade Corporation has been largely ignored by financial historians. Based on substantial archival research, this book rectifies this neglect and makes an important contribution to the financial history of interwar Britain.

This book is the first comprehensive history of the British Trade Corporation, which was constituted under a Royal Charter on 21st April 1917. Its charter was meant to last for sixty years, but in 1926, after a turbulent existence of only nine years, it was amalgamated with the Anglo-Austrian Bank, and absorbed into the Anglo-International Bank. The corporation together with its two main subsidiaries, the Levant Company and the National Bank of Turkey, conducted business not only in Britain but in Russia, Turkey, the Middle East and in Continental Europe. Although the corporation was not an agent of empire, it reflected Britain’s imperialistic ambitions after the First World War. As a result, it invested in some of the most unstable regions of the world. It was also severely affected by British foreign policy, which was often misjudged and, at times, duplicitous, resulting in serious damage to British trade. Within five years of its launch, the British Trade Corporation needed to be refinanced. The economic downturn in the early 1920s and ongoing hostilities in Eastern Europe and the Near East meant that it struggled to survive. Its difficulties reflected many of those faced by Britain in general after the war and the need to come to terms with the new realities of the post-war world.Despite its innovative attempt to address the perceived deficiencies in Britain’s financial system, especially in respect of industrial finance, the British Trade Corporation has been largely ignored by financial historians. Based on substantial archival research, this book rectifies this neglect and makes an important contribution to the financial history of interwar Britain.

This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field, this book reviews state-of-the-art knowledge with emphasis on multidisciplinary decision making and management of head and neck cancer. Significant detail is provided on a wide range of topics including:  oral potentially malignant disorders, cell-based assays for drug discovery and drug evaluation, the role of precision medicine (genomics and beyond), innovations in systemic therapy (including metronomic chemotherapy and immunotherapy), surgery (including partial laryngeal surgery and quality of reconstruction) and radiotherapy (including FLASH-therapy) in different disease settings taking into account their impact on benefit/risk ratio.In addition, specific topics such as hypoxia, hyperthermia, intratumoral drug administration, noninvasive biomarkers, local therapy in metastatic head and neck cancer, sentinel lymph node biopsy in cN0 early-stage oral cavity cancer, prognostic factors in HPV-positive oropharyngeal cancer, molecular characterization of salivary gland cancer (including implications for treatment) and strategies to improve outcome in salivary duct carcinoma are discussed.All disciplines involved in the treatment of head and neck cancer are covered with a focus on translation into daily practice. The 9th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment and care of patients with head and neck cancer.

This book offers a selection of the critical current issues and challenges in head and neck cancer.  It covers most key concepts of the subject, from diagnostic challenges to multidisciplinary decision-making aspects in head and neck oncology. Starting with the Make Sense Campaign and examining its impact on clinical practice, readers also gain insight into current and novel therapeutic approaches, including radiotherapy, cytotoxic chemotherapy, targeted therapy, and immunotherapy, as well as the importance of adequate supportive care. Surgical interventions such as endoscopic surgery, salvage surgery, dentistry and implants are also discussed. Moreover, the changing respective roles of the involved caregivers are highlighted and extensively discussed. The chapters are based on the latest data presented at the 5th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.Taking into account the ample currenttreatment options for patients with head and neck cancer and discussing side effects, survivorship issues and treatment in the elderly, this book provides and up-to-date coverage of all the critical topics in the field. Highlighting the increasing importance of decision-making in recurrent and metastatic head and neck cancer as well as quality of life and end of life issues, this reference book also emphasizes a multidisciplinary approach that plays such an important role in the outcome for this disease.  Edited by a team of world leaders in Head and Neck Cancer this volume serves as an easy reference to the head and neck oncology practitioner and provides an up-to-date overview for specialists the field.

This book offers a selection of the critical current issues and challenges in head and neck cancer.  It covers most key concepts of the subject, from diagnostic challenges to multidisciplinary decision-making aspects in head and neck oncology. Starting with the Make Sense Campaign and examining its impact on clinical practice, readers also gain insight into current and novel therapeutic approaches, including radiotherapy, cytotoxic chemotherapy, targeted therapy, and immunotherapy, as well as the importance of adequate supportive care. Surgical interventions such as endoscopic surgery, salvage surgery, dentistry and implants are also discussed. Moreover, the changing respective roles of the involved caregivers are highlighted and extensively discussed. The chapters are based on the latest data presented at the 5th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field.Taking into account the ample currenttreatment options for patients with head and neck cancer and discussing side effects, survivorship issues and treatment in the elderly, this book provides and up-to-date coverage of all the critical topics in the field. Highlighting the increasing importance of decision-making in recurrent and metastatic head and neck cancer as well as quality of life and end of life issues, this reference book also emphasizes a multidisciplinary approach that plays such an important role in the outcome for this disease.  Edited by a team of world leaders in Head and Neck Cancer this volume serves as an easy reference to the head and neck oncology practitioner and provides an up-to-date overview for specialists the field.

This world was increasingly challenged in the interwar period, being replaced by floating exchange rates, trade protectionism and restrictions on capital movements.This book fills a gap in the historiography of British banking by recovering the histories of long-forgotten merchant banks rather than focusing on the better-known firms.

This book provides an overview of the latest advances in head and neck cancer using a multidisciplinary approach. Commencing with a discussion of epidemiological and diagnostic aspects, including the role of vaccination and key pathological features, the book then follows by examining the role of oncogenomics, proteomics, next generation sequencing and homologous recombination function in predicting outcomes. The topics are presented by epidemiologists, pathologists and basic scientists with further contributions from medical oncologists, head and neck cancer surgical specialists (ORL /HNS), and radiation oncologists in chapters that discuss therapeutic approaches for oral, oropharyngeal and thyroid cancer. Special topics such as the development of novel staging classifications, optimal larynx preservation approaches for laryngeal and hypopharyngeal cancer, surgical reconstruction, new surgical approaches in oropharynx cancer, potential for treatment de-escalation, systemic therapyin nasopharyngeal cancer and salivary gland tumors and treatment approaches for tumors of unknown primary site are discussed in detail. Finally, the role of immunotherapy in the field is highlighted.The chapters are based on the latest data presented at the 6th Trends in Head and Neck Oncology Conference and reflect the most up-to-date information in the field. They are written by many of the most internationally acclaimed authors in the field and are therefore an excellent source for all those interested or actively working in the field of head and neck cancer.